View in EDS HTML Full Text PDF Full Text

Extended‐release buprenorphine treatment for opioid use disorder: A mixed‐methods study of response and experience.

Saved in:
Bibliographic Details
Title: Extended‐release buprenorphine treatment for opioid use disorder: A mixed‐methods study of response and experience.
Authors: Lowry, Natalie, McKechnie, Andrew, Day, Edward, Gilvarry, Eilish, Cowden, Fiona, Evans, Rachel, Locke, Rosie, Murray, Robbie, Vanderwaal, Rob, Johnstone, Stacey, Hoare, Zoe, Kelleher, Michael, Mitcheson, Luke, Marsden, John
Source: Addiction. Oct2025, Vol. 120 Issue 10, p2055-2066. 12p.
Subjects: Substance abuse, Cocaine, Benzodiazepines, Methadone hydrochloride, Sublingual drug administration, Research funding, Statistical sampling, Interviewing, Questionnaires, Oral drug administration, Treatment effectiveness, Randomized controlled trials, Descriptive statistics, Tranquilizing drugs, Sound recordings, Thematic analysis, Drug use testing, Research, Research methodology, Urinalysis, Narcotics, Comparative studies, Data analysis software, Immunoassay, Buprenorphine, Drug abusers, Adults
Geographic Terms: United Kingdom
Abstract: Background and aims: An investigation of 24 weeks of extended‐release buprenorphine (BUP‐XR; Sublocade®) treatment for adults with opioid use disorder (OUD). Study aims were to characterise variations in clinical response, investigate personal factors influencing BUP‐XR experience and identify opportunities to tailor treatment interventions. Design: A convergent parallel mixed‐methods evaluation embedded in a five‐centre, phase 3, randomised controlled trial of BUP‐XR versus daily oral methadone or sublingual buprenorphine. Setting: Four of five National Health Service addictions treatment clinics in England and Scotland from the trial. Participants: Participants were recruited after they completed the 24‐week endpoint. Forty‐nine participants (31%) from the trial completed the qualitative interview. Measurements Three outcome measures from the trial's dataset were used descriptively: (1) fortnightly clinic visit administered TimeLine Follow‐Back interview and urine drug screen data on use of non‐medical opioids, cocaine and benzodiazepines; (2) the frequency version of the 11‐item Craving Experience Questionnaire administered at baseline and endpoint; and (3) the Structured Clinical Interview for DSM‐5 disorders for diagnosis of early OUD and cocaine use disorder (CUD) remission. Data visualisation (by heatmap) identified drug use response sub‐groups. A topic‐guided, semi‐structured qualitative interview was analysed by Interactive Categorisation. Findings Three response sub‐groups were identified: Group 1 [14 (28.5%) of 49 participants] had the highest level of response, characterised by continuous abstinence from opioids, cocaine and benzodiazepines, improvements in craving control and mental and physical health in the majority, and a high level of remission and satisfaction with care; Group 2 [14 (28.5%) of 49 participants] had the next level of response, characterised by continuous abstinence from opioids, but some with opioid craving and some with compensatory use of cocaine and benzodiazepine to cope with anxiety and stress; Group 3 [21 (43.0%) of 49 participants] were not continuously abstinent from opioids during follow‐up, the majority had dual OUD and CUD at trial enrolment, some reported breakthrough opioid withdrawal symptoms during follow‐up, the majority reported improvements in mental health, but many reported opioid and cocaine cravings and compensatory use of cocaine and benzodiazepines. Conclusions: There appears to be variation in response and experience of extended‐release buprenorphine during the first six months of treatment, depending on substance use and physical health. This highlights the need for tailored treatment plans based on differing individual needs. [ABSTRACT FROM AUTHOR]
Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 187948804
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Extended‐release buprenorphine treatment for opioid use disorder: A mixed‐methods study of response and experience.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Lowry%2C+Natalie%22">Lowry, Natalie</searchLink><br /><searchLink fieldCode="AR" term="%22McKechnie%2C+Andrew%22">McKechnie, Andrew</searchLink><br /><searchLink fieldCode="AR" term="%22Day%2C+Edward%22">Day, Edward</searchLink><br /><searchLink fieldCode="AR" term="%22Gilvarry%2C+Eilish%22">Gilvarry, Eilish</searchLink><br /><searchLink fieldCode="AR" term="%22Cowden%2C+Fiona%22">Cowden, Fiona</searchLink><br /><searchLink fieldCode="AR" term="%22Evans%2C+Rachel%22">Evans, Rachel</searchLink><br /><searchLink fieldCode="AR" term="%22Locke%2C+Rosie%22">Locke, Rosie</searchLink><br /><searchLink fieldCode="AR" term="%22Murray%2C+Robbie%22">Murray, Robbie</searchLink><br /><searchLink fieldCode="AR" term="%22Vanderwaal%2C+Rob%22">Vanderwaal, Rob</searchLink><br /><searchLink fieldCode="AR" term="%22Johnstone%2C+Stacey%22">Johnstone, Stacey</searchLink><br /><searchLink fieldCode="AR" term="%22Hoare%2C+Zoe%22">Hoare, Zoe</searchLink><br /><searchLink fieldCode="AR" term="%22Kelleher%2C+Michael%22">Kelleher, Michael</searchLink><br /><searchLink fieldCode="AR" term="%22Mitcheson%2C+Luke%22">Mitcheson, Luke</searchLink><br /><searchLink fieldCode="AR" term="%22Marsden%2C+John%22">Marsden, John</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Addiction%22">Addiction</searchLink>. Oct2025, Vol. 120 Issue 10, p2055-2066. 12p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Substance+abuse%22">Substance abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Cocaine%22">Cocaine</searchLink><br /><searchLink fieldCode="DE" term="%22Benzodiazepines%22">Benzodiazepines</searchLink><br /><searchLink fieldCode="DE" term="%22Methadone+hydrochloride%22">Methadone hydrochloride</searchLink><br /><searchLink fieldCode="DE" term="%22Sublingual+drug+administration%22">Sublingual drug administration</searchLink><br /><searchLink fieldCode="DE" term="%22Research+funding%22">Research funding</searchLink><br /><searchLink fieldCode="DE" term="%22Statistical+sampling%22">Statistical sampling</searchLink><br /><searchLink fieldCode="DE" term="%22Interviewing%22">Interviewing</searchLink><br /><searchLink fieldCode="DE" term="%22Questionnaires%22">Questionnaires</searchLink><br /><searchLink fieldCode="DE" term="%22Oral+drug+administration%22">Oral drug administration</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+effectiveness%22">Treatment effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Randomized+controlled+trials%22">Randomized controlled trials</searchLink><br /><searchLink fieldCode="DE" term="%22Descriptive+statistics%22">Descriptive statistics</searchLink><br /><searchLink fieldCode="DE" term="%22Tranquilizing+drugs%22">Tranquilizing drugs</searchLink><br /><searchLink fieldCode="DE" term="%22Sound+recordings%22">Sound recordings</searchLink><br /><searchLink fieldCode="DE" term="%22Thematic+analysis%22">Thematic analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+use+testing%22">Drug use testing</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Urinalysis%22">Urinalysis</searchLink><br /><searchLink fieldCode="DE" term="%22Narcotics%22">Narcotics</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Data+analysis+software%22">Data analysis software</searchLink><br /><searchLink fieldCode="DE" term="%22Immunoassay%22">Immunoassay</searchLink><br /><searchLink fieldCode="DE" term="%22Buprenorphine%22">Buprenorphine</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+abusers%22">Drug abusers</searchLink><br /><searchLink fieldCode="DE" term="%22Adults%22">Adults</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22United+Kingdom%22">United Kingdom</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background and aims: An investigation of 24 weeks of extended‐release buprenorphine (BUP‐XR; Sublocade®) treatment for adults with opioid use disorder (OUD). Study aims were to characterise variations in clinical response, investigate personal factors influencing BUP‐XR experience and identify opportunities to tailor treatment interventions. Design: A convergent parallel mixed‐methods evaluation embedded in a five‐centre, phase 3, randomised controlled trial of BUP‐XR versus daily oral methadone or sublingual buprenorphine. Setting: Four of five National Health Service addictions treatment clinics in England and Scotland from the trial. Participants: Participants were recruited after they completed the 24‐week endpoint. Forty‐nine participants (31%) from the trial completed the qualitative interview. Measurements Three outcome measures from the trial's dataset were used descriptively: (1) fortnightly clinic visit administered TimeLine Follow‐Back interview and urine drug screen data on use of non‐medical opioids, cocaine and benzodiazepines; (2) the frequency version of the 11‐item Craving Experience Questionnaire administered at baseline and endpoint; and (3) the Structured Clinical Interview for DSM‐5 disorders for diagnosis of early OUD and cocaine use disorder (CUD) remission. Data visualisation (by heatmap) identified drug use response sub‐groups. A topic‐guided, semi‐structured qualitative interview was analysed by Interactive Categorisation. Findings Three response sub‐groups were identified: Group 1 [14 (28.5%) of 49 participants] had the highest level of response, characterised by continuous abstinence from opioids, cocaine and benzodiazepines, improvements in craving control and mental and physical health in the majority, and a high level of remission and satisfaction with care; Group 2 [14 (28.5%) of 49 participants] had the next level of response, characterised by continuous abstinence from opioids, but some with opioid craving and some with compensatory use of cocaine and benzodiazepine to cope with anxiety and stress; Group 3 [21 (43.0%) of 49 participants] were not continuously abstinent from opioids during follow‐up, the majority had dual OUD and CUD at trial enrolment, some reported breakthrough opioid withdrawal symptoms during follow‐up, the majority reported improvements in mental health, but many reported opioid and cocaine cravings and compensatory use of cocaine and benzodiazepines. Conclusions: There appears to be variation in response and experience of extended‐release buprenorphine during the first six months of treatment, depending on substance use and physical health. This highlights the need for tailored treatment plans based on differing individual needs. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=187948804
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/add.70106
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 2055
    Subjects:
      – SubjectFull: Substance abuse
        Type: general
      – SubjectFull: Cocaine
        Type: general
      – SubjectFull: Benzodiazepines
        Type: general
      – SubjectFull: Methadone hydrochloride
        Type: general
      – SubjectFull: Sublingual drug administration
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Statistical sampling
        Type: general
      – SubjectFull: Interviewing
        Type: general
      – SubjectFull: Questionnaires
        Type: general
      – SubjectFull: Oral drug administration
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Randomized controlled trials
        Type: general
      – SubjectFull: Descriptive statistics
        Type: general
      – SubjectFull: Tranquilizing drugs
        Type: general
      – SubjectFull: Sound recordings
        Type: general
      – SubjectFull: Thematic analysis
        Type: general
      – SubjectFull: Drug use testing
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Urinalysis
        Type: general
      – SubjectFull: Narcotics
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Data analysis software
        Type: general
      – SubjectFull: Immunoassay
        Type: general
      – SubjectFull: Buprenorphine
        Type: general
      – SubjectFull: Drug abusers
        Type: general
      – SubjectFull: Adults
        Type: general
      – SubjectFull: United Kingdom
        Type: general
    Titles:
      – TitleFull: Extended‐release buprenorphine treatment for opioid use disorder: A mixed‐methods study of response and experience.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lowry, Natalie
      – PersonEntity:
          Name:
            NameFull: McKechnie, Andrew
      – PersonEntity:
          Name:
            NameFull: Day, Edward
      – PersonEntity:
          Name:
            NameFull: Gilvarry, Eilish
      – PersonEntity:
          Name:
            NameFull: Cowden, Fiona
      – PersonEntity:
          Name:
            NameFull: Evans, Rachel
      – PersonEntity:
          Name:
            NameFull: Locke, Rosie
      – PersonEntity:
          Name:
            NameFull: Murray, Robbie
      – PersonEntity:
          Name:
            NameFull: Vanderwaal, Rob
      – PersonEntity:
          Name:
            NameFull: Johnstone, Stacey
      – PersonEntity:
          Name:
            NameFull: Hoare, Zoe
      – PersonEntity:
          Name:
            NameFull: Kelleher, Michael
      – PersonEntity:
          Name:
            NameFull: Mitcheson, Luke
      – PersonEntity:
          Name:
            NameFull: Marsden, John
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: Oct2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 09652140
          Numbering:
            – Type: volume
              Value: 120
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Addiction
              Type: main
ResultId 1